Effect of Renal Impairment on Enpatoran Pharmacokinetics

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513393-22-00

Acronym

MS200569_0051

Enrollment

Registered

2024-08-06

Start date

2024-09-04

Completion date

Unknown

Last updated

2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

as well as dermatomyositis (DM) and polymyositis (PM)., Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Germany

Outcome results